Is Similar the Same? Biosimilars in Inflammatory Bowel Disease and Rheumatoid Arthritis

The primary goal of this activity is to provide clinicians who treat patients with inflammatory bowel disease(IBD) and rheumatoid arthritis (RA) with a better understanding of the manufacturing process for biosimilars and secondarily, present the major patient questions and concerns when it comes to switching from an originator therapy to a biosimilar so that both the clinicians and patients are better prepared for those discussions. Feedback from more than 250 patients helped inform the content for this activity. Through a patient/provider panel discussion, our hope is to identify the major educational gaps and concerns among patients and clinicians and to identify methods for effective co-production of treatment plans that are mutually agreeable to all stakeholders.

Target Audience

The target audience for this initiative includes specialists in gastroenterology, rheumatology, primary care providers, nurse practitioners, physician assistants and pharmacists involved in the treatment and care of patients with RA and IBD as well as the patients themselves.

Learning Objectives

After completing this education, participants will be able to:

  • Compare and contrast biosimilars with reference (originator) biologics
  • Assess the efficacy, safety, and immunogenicity of approved biosimilars relative to their reference biologics
  • Discuss considerations to take into account when switching a patient’s medication from a reference biologic to a biosimilar
  • Appraise the questions and uncertainties faced by specialists, primary care providers, patients, and pharmacists as biosimilar drugs are adopted in RA and IBD

Additional Information

Partner: 
myCME
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
Course opens: 
04/06/2021
Course expires: 
04/06/2021
Rating: 
0

Raymond K. Cross, MD
Professor of Medicine and Director of the Inflammatory Bowel Disease Program
University of Maryland School of Medicine
Baltimore, MD

Dr. Cross has disclosed that he has received consulting fees from AbbVie, Janssen, Samsung Bioepis, and Takeda and fees for non-CME/CE services from Pfizer.

Moderator

Suz Schrandt
Founder, CEO, & Chief Patient Advocate
ExPPect
Arlington, VA

Ms. Schrandt has nothing to disclose.

Faculty

Bernadette C. Siaton, MD, MEdHP
Assistant Professor of Medicine and Rheumatology Fellowship Program Director
University of Maryland School of Medicine
Baltimore, MD

Dr. Siaton has nothing to disclose.

Michele Andwele
Patient Advocate

Ms. Andwele has nothing to disclose.

Lisa Diven
Patient Advocate

Ms. Diven has nothing to disclose.

This activity is jointly provided by Global Education Group and FACTORx.

Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and FACTORx. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

Global Education Group designates this continuing education activity for 1.25 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-052-H01-P)
This is a knowledge based activity.

Additional Credit Information

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category 1 credit for completing this program.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
Please login or register to take this course.

This course is offered through MyCME. To take this course you will be redirected to MyCME's website. You must have an account with MyCME in order to complete this activity. 

MOCINGBIRD continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!